CRISPR Therapeutics AG
CRSP
Peringkat dalam Saham
#3549
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering... CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
Harga Saham
$50.19
Kapitalisasi Pasar
$4.85B
Perubahan (1 hari)
1.92%
Perubahan (1 tahun)
-27.41%
Negara
CH
Perdagangan CRISPR Therapeutics AG (CRSP)
Kategori
Healthcare
Margin Operasi untuk CRISPR Therapeutics AG (CRSP)
Margin Operasi per October 2026 TTM: -3,971.53%
Menurut laporan keuangan dan harga saham terbaru dari CRISPR Therapeutics AG, margin operasi saat ini (TTM) adalah -3,971.53%. Pada akhir 2023, margin operasi perusahaan adalah -59.95%.
Riwayat margin operasi untuk CRISPR Therapeutics AG dari 2014 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Mengubah |
|---|---|---|
| 2026 (TTM) | -3,971.53% | 197.93% |
| 2024 | -1,333.05% | 2,123.60% |
| 2023 | -59.95% | -99.96% |
| 2022 | -154,394.72% | -377,500.93% |
| 2021 | 40.91% | -100.06% |
| 2020 | -65,273.48% | -404,520.57% |
| 2019 | 16.14% | -100.32% |
| 2018 | -5,087.80% | 3,126.46% |
| 2017 | -157.69% | -88.05% |
| 2016 | -1,319.33% | -87.33% |
| 2015 | -10,416.60% | 0.00% |
| 2014 | 0.00% | 0.00% |
Margin Operasi untuk perusahaan sejenis atau pesaing
| Perusahaan | Margin Operasi | Perbedaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -100.01% |
US
|
|
| -149.01% | -99.96% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.01% |
NL
|
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.